Does OPTINAB strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel (nab) - gemcitabine (gem)?,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Does OPTINAB strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel (nab) - gemcitabine (gem)?
Journal of Clinical Oncology ( IF 45.3 ) Pub Date : 2016-05-20 , DOI: 10.1200/jco.2016.34.15_suppl.e15672
Wasif M. Saif ₁ , Valerie Relias ₂ , Sanjay Hegde ₃ , Douglas W Hackenyos ₃ , Lisa Ralph ₃ , Antonia Maloney ₃ , Melissa H Smith ₂ , Martin D. Goodman ₃

Affiliation

e15672Background: MPACT study showed survival benefit of nab-gem vs. gem in APC [Von Hoff D, NEJM 2013]. Sensory peripheral neuropathy is a dose-limiting toxicity associated with nab. Neuromodulato...

中文翻译：

OPTINAB 策略（“走走停停”）是否适用于白蛋白结合型紫杉醇 (nab) - 吉西他滨 (gem) 治疗晚期胰腺癌 (APC)？

e15672背景：MPACT 研究表明，nab-gem 与 gem 在 APC 中的生存获益 [Von Hoff D, NEJM 2013]。感觉周围神经病变是与 nab 相关的剂量限制性毒性。神经调节...

更新日期：2016-05-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>